Drugs / Amiloride
Amiloride
also known as
amiloride hydrochloride · Amiclaran · Amilamont · Amilorid · Amilorida · amiloride chloride · amiloride HCl · Amiloride Hcl 5mg Tab · +16 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MODURETIC 5-50 | — | 1981-10-05 | fda.gov ↗ |
Trials 39
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04181008 | Sep 2020 → Aug 2022 | — | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT01804777 | Mar 2013 → Dec 2014 | hypertensive disorder, proteinuria, type 2 diabetes mellitus | University of New Mexico | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01095133 | Mar 2010 → Sep 2011 | dyspepsia, gastroesophageal reflux disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT00547053 | Dec 2006 → Jan 2008 | cystic fibrosis | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01146197 | Feb 2010 → Dec 2012 | Gitelman syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT06224673 | Jun 2026 → Nov 2029 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | Laura Huppert, MD, BA | Recruiting | No outcome recorded |
| Phase 2 | NCT07634068 | Jun 2026 → Jun 2027 expected | cerebrovascular disorder | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06923709 | Oct 2024 → Aug 2025 overdue | chronic kidney disease, proteinuria | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04063540 | Aug 2020 → Dec 2027 expected | migraine with aura | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 2 | NCT01910259 | Dec 2014 → Jun 2018 | secondary progressive multiple sclerosis | University College, London | Completed | Missed primary |
| Phase 2 | NCT00394394 | Feb 2005 → ? | hypertensive disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 2 | NCT00274391 | Jul 2001 → Apr 2004 | cystic fibrosis | University of North Carolina | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03837626 | Jul 2019 → Oct 2024 | — | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 2/3 | NCT01228214 | Mar 2011 → Apr 2013 | coronary artery disorder | University of Carabobo | Unknown | No outcome recorded |
| Phase 2/3 | NCT01231165 | Feb 2009 → May 2010 | coronary artery disorder | University of Carabobo | Completed | No outcome recorded |
| Phase 38 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT05079789 | Jun 2020 → Nov 2022 | nephrotic syndrome | University Hospital Tuebingen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03928145 | Nov 2019 → Jul 2021 | essential hypertension | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 3 | NCT06416735 | Sep 2018 → Jul 2020 | essential hypertension, genetic | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 3 | NCT02896621 | Dec 2014 → Feb 2016 | hypertensive disorder, obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT01896661 | Dec 2014 → Dec 2015 | hypertensive disorder, obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | Missed primary |
| Phase 3 | NCT01191450 | Aug 2011 → Aug 2013 | hypertensive disorder | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01210365 | Jan 2011 → Mar 2013 | congestive heart failure | Eurofarma Laboratorios S.A. | Terminated | No outcome recorded |
| Phase 3 | NCT00970931 | Jul 2010 → Sep 2014 | hypertensive disorder | Hospital de Clinicas de Porto Alegre | Completed | Met primary |
| Phase 48 trials · 1 met primary | ||||||
| Phase 4 | NCT05044611 | Jan 2023 → Mar 2025 overdue | bipolar disorder | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04331691 | Nov 2020 → May 2024 | resistant hypertension | Yonsei University | Completed | Met primary |
| Phase 4 | NCT03170336 | Mar 2018 → Aug 2020 | chronic kidney disease | Guangdong Provincial People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02847338 | Nov 2016 → Oct 2023 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02832973 | Sep 2015 → Dec 2017 | resistant hypertension | Sao Jose do Rio Preto Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02522650 | Jul 2013 → Oct 2021 | proteinuria | Georgetown University | Unknown | No outcome recorded |
| Phase 4 | NCT02122731 | Nov 2010 → Jul 2012 | hypertensive disorder, proteinuria, type 2 diabetes mellitus | Ib Abildgaard Jacobsen | Completed | No outcome recorded |
| Phase 4 | NCT01308983 | Sep 2010 → Dec 2012 | hypertensive disorder | Augusta University | Unknown | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT03036748 | Jan 2017 → Sep 2021 | — | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT01918488 | Oct 2013 → Dec 2014 | diabetic kidney disease, hypertensive disorder | University of Southern Denmark | Unknown | No outcome recorded |
| — | NCT01246180 | Oct → Dec 2010 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
| — | NCT00424801 | Jan 2007 → Dec 2008 | coronary microvascular disorder, essential hypertension | University of Aarhus | Terminated | No outcome recorded |
| — | NCT00429897 | Aug 2006 → Jul 2007 | hypertensive disorder | University of Cambridge | Unknown | No outcome recorded |
| — | NCT00285805 | Feb → Oct 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00141596 | Jul 2003 → Oct 2006 | hypertensive disorder | St George's, University of London | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00004705 | Sep 1996 → Jan 1999 | cystic fibrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 0 | NCT01733680 Comparator | Sep 2012 → Sep 2015 | attention deficit-hyperactivity disorder | State University of New York - Upstate Medical University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05753059 Comparator | Aug 2023 → Jun 2028 expected | heart failure | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT00857909 Comparator | Jan 2009 → Jul 2010 | hypertensive disorder | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 2 | NCT02824718 Comparator | Jun 2017 → May 2020 | autosomal dominant hypocalcemia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02497300 Comparator | Mar 2015 → Jul 2021 | chronic kidney disease, proteinuria | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT01879527 Comparator | Mar 2014 → Apr 2016 | optic neuritis | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01802489 Comparator | Feb 2013 → Nov 2015 | multiple sclerosis, optic neuritis | University of Oxford | Completed | No outcome recorded |
| Phase 2/3 | NCT02525796 Comparator | Jan 2016 → Oct 2021 | primary hyperparathyroidism | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 3 | NCT00971165 Comparator | Jul 2010 → Sep 2014 | hypertensive disorder | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT05228574 Comparator | Mar 2022 → Jun 2025 | autosomal dominant polycystic kidney disease | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02875886 Comparator | Sep 2016 → Apr 2018 | chronic kidney disease | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01388088 Comparator | Sep 2010 → Feb 2012 | hypertensive disorder | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 4 | NCT02351973 Comparator | Nov 2009 → Jul 2015 | essential hypertension | University of Cambridge | Unknown | No outcome recorded |
| Phase 4 | NCT01011660 Comparator | Oct 2007 → Aug 2012 | essential hypertension | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| — | NCT01195805 Comparator | Aug 2010 → Aug 2015 | essential hypertension | Regional Hospital Holstebro | Completed | No outcome recorded |
| — | NCT00709137 Comparator | Oct 2008 → Oct 2010 | hypertensive disorder | VA Salt Lake City Health Care System | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00478335 Background | May 2007 → Oct 2012 | nephrogenic diabetes insipidus | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 58 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amiloride | “combination of furosemide (40 mg) and amiloride (10 mg) compared with furosemide alone” NCT01210365 ↗56“Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning” NCT01896661 ↗ “metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene” NCT00684489 ↗ “amiloride 5 mg/day (MODAMIDE®)” NCT02824718 ↗ “10-20 mg/day amiloride” NCT01146197 ↗ |
| Known as | Amiclaran | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amilamont | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amilorid | “5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid.” NCT01879527 ↗ |
| Known as | Amilorida | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | amiloride chloride | “Diurisa® (furosemide 40 mg + amiloride chloride 10 mg)” NCT01210365 ↗ |
| Known as | amiloride HCl | “our recent observation that reversal of an abnormal low RBC K content in hypertensive patients receiving low doses of pyrazinoylguanidine hydrochloride (amiloride HCl, 5 mg),...” NCT01231165 ↗ |
| Known as | Amiloride Hcl 5mg Tab | “Drug: Amiloride Hcl 5mg Tab” NCT05228574 ↗ |
| Known as | amiloride HCl/2H2O | “Amiloride will be obtained as a sterile powder in the form of amiloride HCl/2H2O .” NCT00285805 ↗ |
| Known as | amiloride hydrochloride | “the most promising compound was the 3,5-diamino-6-chloro-N- \[diaminomethylene\]pyrazinecarboxamide dihydrate derivative, amiloride hydrochloride recently published as a new...” NCT01228214 ↗1“Subjects will take either amiloride hydrochloride or placebo for 8 weeks.” NCT01733680 ↗ |
| Known as | Amiloride hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amiloride hydrochloride component of hydro-ride | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amiloride hydrochloride component of moduretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amiloride hydrochloride dehydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amiloride hydrochloride dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amiloridi hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amilospare 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amipramidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Amoride | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Anhydrous amiloride hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Berkamil | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Hydro-ride | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Midamor | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | NSC-755847 | ChEMBL registry synonym — accepted as the source's own label CHEMBL945 ↗ |
| Known as | Pyrazinoylguanidine Hydrochloride | “Randomized Double-Blind Placebo-Controlled Study of Pyrazinoylguanidine Hydrochloride (Amiloride) in Subjects With Coronary Artery Disease” NCT01228214 ↗ |
| Action | Inhibit | “the ASIC-inhibitor, amiloride, can block heartburn elicited by acid-perfusion” NCT01095133 ↗ |
| Modality | Small molecule | — CHEMBL945 ↗ |
| Route | Inhaled | “Patients are randomized to receive one of 4 different aerosols (vehicle; UTP; amiloride; or UTP plus amiloride), which is inhaled for 20 minutes.” NCT00004705 ↗ |